Stavros V. Konstantinides et al. JACC 2017;69:

Slides:

Advertisements

Similar presentations

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Thrombolysis for Pulmonary Embolism and Risk of All-Cause.

Advertisements

Volume 187, Issue 6, Pages (June 2012)

From: Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseThe REDUCE Randomized Clinical Trial.

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Volume 66, Issue 6, Pages (December 2015)

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Volume 115, Issue 2, Pages (February 1999)

by Alexander Leaf, Christine M

Copyright © 2013 American Medical Association. All rights reserved.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Noriko Kikuchi et al. JACEP 2016;2:

Robert W. Yeh et al. JACC 2017;70:

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Nat. Rev. Urol. doi: /nrurol

Prognostic Value of Low Blood Glucose at the Presentation of E

Dean J. Kereiakes et al. JACC 2017;70:

Kenshi Hayashi et al. JACEP 2016;2:

Belinda Gray et al. JCHF 2013;1:

David F. Katz et al. JACEP 2016;j.jacep

ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.

Stavros Stavrakis et al. JACEP 2015;1:1-13

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Wayne L. Miller et al. JCHF 2013;1:

Giuseppe Boriani et al. JACEP 2016;2:

Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.

Mohit K. Turagam et al. JACEP 2017;3:

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Mahesh Anantha Narayanan et al. JACEP 2017;3:

Mintu P. Turakhia et al. JACEP 2016;2:

Kaplan-Meier curves for overall survival (OS) probability.

Physical Counterpressure Maneuver (PC) Trial

Yoshitaka Kimura et al. JACEP 2016;2:

Kenshi Hayashi et al. JACEP 2016;2:

David F. Katz et al. JACEP 2017;3:20-28

Neal A. Chatterjee et al. JCHF 2014;2:

P. Michael Grossman et al. JCIN 2009;2:

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Volume 12, Issue 8, Pages (August 2013)

Simon W. Rabkin et al. JACEP 2017;3:

Mahesh Anantha Narayanan et al. JACEP 2017;j.jacep

Nat. Rev. Urol. doi: /nrurol

Volume 66, Issue 2, Pages (August 2004)

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

Glenn N. Levine et al. JACC 2011;58:e44-e122

A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Kaplan-Meier survival estimates for major cardiovascular events.

Demographic Characteristics of Patients Treated With Statins Versus Those Not Treated With Statins Goldberger JJ, et al. J Am Coll Cardiol 2006;48:

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Maxime Berthelot-Richer et al. JIMG 2016;9:

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Kaplan-Meier analysis for the cumulative percentage of patients who remained hospitalized according to presence or absence of ARF with or without other.

Kaplan-Meier curves of ventricular arrhythmia–related events (A), death from MI (B), or both end points combined (C). Kaplan-Meier curves of ventricular.

FILM protein signature predicts poor survival in nontreated stage-IB lung adenocarcinoma. FILM protein signature predicts poor survival in nontreated stage-IB.

Kaplan-Meier estimates of all-cause mortality at 30 days.

Mortality rate according to our integrated index that combines DH and exercise capacity. Mortality rate according to our integrated index that combines.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Daniele Muser et al. JACEP 2017;j.jacep

Overall and recurrence-free survival.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Kaplan-Meier event-free survival from ipsilateral stroke for patients with near occlusion, pooled data from the NASCET and ECST. The 3-year intention-to-treat.

Presentation transcript:

Stavros V. Konstantinides et al. JACC 2017;69:1536-1544 Thrombolysis for Pulmonary Embolism: Kaplan-Meier Survival Curves of Patients Randomized to Tenecteplase Compared With Placebo Kaplan-Meier curves showing the cumulative risk of death in patients with intermediate-risk pulmonary embolism who were randomized to tenecteplase versus placebo in the PEITHO (Pulmonary Embolism Thrombolysis) trial. A total of 709 patients, corresponding to 71% of the overall intention-to-treat population, were randomized by 28 study sites that signed the third protocol amendment extending the follow-up period to at least 24 months. Long-term follow-up extended over a median period of 37.8 months, with an interquartile range of 24.6 to 54.8 months. Survival status was assessed in 353 of 359 (98.3%) patients in the thrombolysis arm and in 343 of 350 (98.0%) patients in the placebo arm. Overall long-term mortality rates did not differ significantly between the 2 treatment arms: 20.3% and 18.0%, respectively (log-rank; p = 0.43). Stavros V. Konstantinides et al. JACC 2017;69:1536-1544 2017 American College of Cardiology Foundation